Inhaler Therapy: Types, Technique, and Medications
Inhaler therapy is the primary delivery method for most medications used in obstructive and inflammatory lung diseases, directing drug particles directly to airway tissue at doses far smaller than systemic alternatives. This page covers the major inhaler device categories, the physiological mechanism behind aerosol deposition, the clinical scenarios where specific devices are preferred, and the criteria that distinguish one device class from another. Understanding these distinctions is foundational to interpreting pulmonary disease management and the broader medications landscape for lung disease.
Definition and scope
Inhaler therapy encompasses any system that aerosolizes a pharmaceutical compound and delivers it through the mouth and upper airway to the bronchial tree and alveolar surface. The U.S. Food and Drug Administration (FDA) regulates inhaler devices as combination drug-device products under 21 CFR Part 3 and the Federal Food, Drug, and Cosmetic Act, meaning both the propellant or formulation and the physical device undergo review before approval.
Three primary device platforms dominate clinical use in the United States:
- Pressurized Metered-Dose Inhalers (pMDIs) — A pressurized canister releases a precise aerosol dose via a propellant (historically chlorofluorocarbons, now hydrofluoroalkane/HFA following the Montreal Protocol transition completed by 2009). Particle size from standard pMDIs typically ranges from 2 to 5 micrometers mass median aerodynamic diameter (MMAD).
- Dry Powder Inhalers (DPIs) — Breath-actuated devices that require a sufficient inspiratory flow rate, generally above 30–60 liters per minute depending on device design, to disaggregate the powder into respirable particles.
- Nebulizers — Devices that convert liquid medication into a continuous fine mist using compressed air (jet nebulizers) or ultrasonic/mesh technology. Mesh nebulizers such as vibrating-mesh designs achieve output particle sizes in the 3–5 micrometer range (National Institutes of Health, National Heart, Lung, and Blood Institute [NHLBI]).
Spacers and valved holding chambers (VHCs) are accessory devices used exclusively with pMDIs to slow aerosol velocity, reduce oropharyngeal deposition, and compensate for poor hand-breath coordination.
The regulatory context for pulmonary medicine shapes which formulations reach patients, including FDA's post-market surveillance requirements for combination products under 21 CFR Part 4.
How it works
Drug deposition in the lung depends on three physical mechanisms: inertial impaction, gravitational sedimentation, and Brownian diffusion. Particles larger than 10 micrometers impact in the oropharynx before reaching the bronchi. Particles between 1 and 5 micrometers reach the bronchioles and alveolar regions through sedimentation. Particles smaller than 0.5 micrometers are largely exhaled without deposition.
Optimal lung deposition for most inhaled corticosteroids and bronchodilators occurs with particles in the 1–5 micrometer range. However, device-specific factors modify actual delivery:
- pMDI without spacer: Typical lung deposition is approximately 10–20% of the nominal dose (FDA Drug Approval Databases; Dolovich et al., Chest 2005).
- pMDI with VHC: Deposition can increase to 30–40% of nominal dose by reducing high-velocity particle impaction in the oropharynx.
- DPI: Deposition is highly dependent on patient inspiratory flow; clinical studies show deposition efficiency ranging from 12–40% depending on device design and patient effort.
- Nebulizer: Delivers drug continuously over 5–15 minutes; total lung deposition varies from 10–15% for conventional jet nebulizers to higher fractions with optimized mesh designs.
The NHLBI's National Asthma Education and Prevention Program (NAEPP) Expert Panel Report 3 identifies inhaler technique as a primary determinant of therapeutic outcome, noting that incorrect technique is a leading cause of treatment failure in asthma management.
Common scenarios
Inhaler therapy appears across the full spectrum of obstructive, inflammatory, and fibrotic lung disease. The clinical scenarios below represent the most established applications.
Asthma: Short-acting beta-2 agonists (SABAs), principally albuterol, are delivered via pMDI or nebulizer for acute bronchospasm. Inhaled corticosteroids (ICS) such as fluticasone and budesonide are the cornerstone of persistent asthma maintenance. Combination ICS/long-acting beta-2 agonist (LABA) products (e.g., fluticasone/salmeterol, budesonide/formoterol) are prescribed per NAEPP step-care guidelines for moderate-to-severe persistent asthma.
COPD: The Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines recommend long-acting muscarinic antagonists (LAMAs) and LABAs as first-line maintenance therapy for COPD. Tiotropium (a LAMA delivered via DPI or soft mist inhaler) demonstrated reduced exacerbation frequency versus placebo in the 4-year UPLIFT trial (17,135 patients, published in New England Journal of Medicine, 2008).
Pediatric populations: Children under age 5 typically cannot generate adequate inspiratory flow for DPI use. pMDI with VHC — and a facemask for children under 4 — is the preferred device per pediatric pulmonology guidelines from the American Academy of Pediatrics.
Acute exacerbations and hospital settings: Continuous or frequently dosed nebulization is standard in emergency and intensive care settings where patients cannot coordinate inhaler actuation or generate sufficient inspiratory effort.
Pulmonary fibrosis and specialized delivery: Inhaled pirfenidone formulations and aerosolized antibiotics (e.g., tobramycin inhalation solution for chronic Pseudomonas infection in bronchiectasis) represent device-specific prescribing requirements documented in FDA-approved prescribing information.
Decision boundaries
Selecting between pMDI, DPI, and nebulizer involves measurable clinical criteria rather than preference alone.
| Factor | pMDI | DPI | Nebulizer |
|---|---|---|---|
| Required inspiratory flow | Low (any effort with VHC) | 30–60 L/min minimum | None |
| Coordination requirement | High (without spacer) | Low (breath-actuated) | None |
| Portability | High | High | Low |
| Age suitability | All ages (with VHC/mask) | Generally ≥6 years | All ages |
| Cost (device) | Low–moderate | Moderate–high | Moderate (device) + consumables |
The FDA requires labeled prescribing information for every approved inhaler to include device-specific instructions for use (IFU), and the agency has issued guidance documents (FDA Guidance for Industry: Metered Dose Inhaler and Dry Powder Inhaler Drug Products, 1998; updated drafts available at FDA.gov) addressing critical-quality attributes for aerosol performance.
Switching device classes without reassessing technique and flow capacity is identified by the GOLD report as a common cause of apparent treatment failure. Patients with chronic cough or suspected poor inhaler adherence may require observed technique assessment before escalating therapy.
The complete index of pulmonary topics provides context for where inhaler therapy fits within the full diagnostic and treatment landscape managed by pulmonologists.
References
- U.S. Food and Drug Administration — Drug-Device Combination Products (21 CFR Part 3 & 4)
- FDA Guidance for Industry: Metered Dose Inhaler (MDI) and Dry Powder Inhaler (DPI) Drug Products
- National Heart, Lung, and Blood Institute (NHLBI) — National Asthma Education and Prevention Program (NAEPP) Expert Panel Report 3
- Global Initiative for Chronic Obstructive Lung Disease (GOLD) — GOLD Report
- American Academy of Pediatrics — Clinical Practice Guidelines
- NIH National Heart, Lung, and Blood Institute — Asthma and COPD Clinical Resources
The law belongs to the people. Georgia v. Public.Resource.Org, 590 U.S. (2020)